Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.36 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | ESRRB | O95718 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL132110 | 1.00 | CTSK (0.39) | CTSKSMN1; SMN2GRIK1GRIK2TSHR | |
| SCHEMBL13706426 | 0.83 | SMN1; SMN2 (0.37) | SMN1; SMN2TSHRMEN1KMT2ACA14 | |
| SCHEMBL7668341 | 0.82 | — | — | |
| SCHEMBL3866367 | 0.81 | ALDH1A1 (0.37) | CTSKGRIK1GRIK2 | |
| SCHEMBL11865860 | 0.80 | CTSK (0.40) | CTSKSMN1; SMN2GRIK1GRIK2TSHR | |
| SCHEMBL11865851 | 0.80 | CTSK (0.40) | CTSKSMN1; SMN2GRIK1GRIK2TSHR | |
| SCHEMBL28363798 | 0.79 | PPARG (0.38) | SMN1; SMN2TSHRMEN1KMT2ACA14 | |
| SCHEMBL9653054 | 0.78 | CTSK (0.36) | CTSKSMN1; SMN2GRIK1GRIK2TSHR | |
| Hydrochloric Acid SCHEMBL29046668 | 0.78 | PPARG (0.37) | SMN1; SMN2TSHRMEN1KMT2ACA14 | |
| SCHEMBL16866044 | 0.78 | SMN1; SMN2 (0.33) | SMN1; SMN2GRIK1GRIK2TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219008-B1 | USE FOR THE TREATMENT OF AN ION EXCHANGE RESIN | MITSUBISHI CHEMICAL UK LTD (GB) | 2024-11-20 | — | — | EP | disclosed |
| EP-4049754-B1 | PROCESS FOR THE TREATMENT OF AN ION EXCHANGE RESIN | MITSUBISHI CHEMICAL UK LTD (GB) | 2024-04-03 | — | — | EP | disclosed |
| EP-4219008-A1 | USE FOR THE TREATMENT OF AN ION EXCHANGE RESIN | Mitsubishi Chemical UK Limited (GB) | 2023-08-02 | — | — | EP | disclosed |
| EP-3862085-B1 | PROCESS FOR THE TREATMENT OF AN ION EXCHANGE RESIN | MITSUBISHI CHEMICAL UK LTD (GB) | 2023-06-07 | — | — | EP | disclosed |
| EP-4049754-A1 | PROCESS FOR THE TREATMENT OF AN ION EXCHANGE RESIN | Mitsubishi Chemical UK Limited (GB) | 2022-08-31 | — | — | EP | disclosed |
| EP-2411147-B1 | PROCESS FOR THE TREATMENT OF AN ION EXCHANGE RESIN | MITSUBISHI CHEMICAL UK LTD (GB) | 2022-04-20 | — | — | EP | disclosed |
| EP-3862085-A1 | PROCESS FOR THE TREATMENT OF AN ION EXCHANGE RESIN | Mitsubishi Chemical UK Limited (GB) | 2021-08-11 | — | — | EP | disclosed |
| US-9821304-B2 | Process for the treatment of an ion exchange resin | LUCITE INTERNATIONAL UK LIMITED (GB) | 2017-11-21 | — | — | US | disclosed |
| US-20140343176-A1 | PROCESS FOR THE TREATMENT OF AN ION EXCHANGE RESIN | Mitsubishi Chemical UK Limited (GB) | 2014-11-20 | — | — | US | disclosed |
| US-8835518-B2 | Process for the treatment of an ion exchange resin | LUCITE INTERNATIONAL UK LIMITED (GB) | 2014-09-16 | — | — | US | disclosed |
| US-20120059073-A1 | PROCESS FOR THE TREATMENT OF AN ION EXCHANGE RESIN | LUCITE INTERNATIONAL UK LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| EP-2411147-A2 | PROCESS FOR THE TREATMENT OF AN ION EXCHANGE RESIN | Lucite International UK Limited (GB) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010109244-A2 | PROCESS FOR THE TREATMENT OF AN ION EXCHANGE RESIN | LUCITE INTERNATIONAL UK LIMITED (GB) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059073-A1 | PROCESS FOR THE TREATMENT OF AN ION EXCHANGE RESIN | RCOR1, RER1, DECR1 | CTSK 4458/4885SMN1; SMN2 2107/4885GRIK1 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.